EDIT – editas medicine, inc. (US:NASDAQ)
Stock Stats
News
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Editas Medicine, Inc. (NASDAQ: EDIT) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Editas Medicine, Inc. (NASDAQ: EDIT) had its price target lowered by analysts at Citigroup Inc. from $16.00 to $15.00. They now have a "buy" rating on the stock.
Form 10-Q Editas Medicine, Inc. For: Mar 31
Form 8-K Editas Medicine, Inc. For: May 08
Form DEFA14A Editas Medicine, Inc.
Form DEF 14A Editas Medicine, Inc. For: Apr 16
Form SC 13G/A Editas Medicine, Inc. Filed by: STATE STREET CORP
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.